Individualized neoantigen vaccine shows 100% three-year disease-free survival in head and neck cancer trial

Transgene and NEC Corporation have reported sustained 100% three-year disease-free survival in patients treated with TG4050, an individualized neoantigen therapeutic vaccine, during the Phase 1 part of a randomized Phase 1/2 trial. The vaccine targets resected, locally advanced HPV-negative head and neck squamous cell carcinoma. The peer-reviewed publication in Nature Communications highlights the durable neoantigen-specific T-cell responses observed, providing strong evidence that this personalized vaccine approach can generate lasting anti-tumor immunity.